Drug intelligence / Profile preview

N0750

Development stage: Phase 3
Lead developer: Eurofarma

Overview

N0750 is an investigational pharmaceutical drug developed by Eurofarma Laboratórios. It is currently in phase 3 clinical trials for the treatment of painful diabetic peripheral neuropathy (PDPN). The drug is being evaluated for its efficacy and safety compared to established monotherapies, specifically duloxetine (Cymbalta) and pregabalin (Lyrica), in reducing pain intensity associated with PDPN. The precise mechanism of action, molecular target(s), and modality of N0750 have not been publicly disclosed as of June 2025[1][2].

Beyond the preview

Go deeper on N0750.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N0750.

Explore the full profile